参考文献/References:
[1] Zalewski A,Macphee C.Role of lipoprotein-associated phospholipase A(2)in atherosclerosis-Biology, epidemiology, and possible therapeutic target[J].Arterioscler Thromb Vasc Biol,2005,25(5):923-931.
[2]Jellinger P,Smith D,Mehta A,et al.American association of clinical endocrinologists\”guidelines for management of dyslipidemia and prevention of atherosclerosis:executive summary[J].Endocrine Practice,2012,18(2):269-293.
[3]Garg PK,Mcclelland RL,Jenny NS,et al.Association of lipoprotein-associated phospholipase A(2)and endothelial function in the Multi-Ethnic Study of Atherosclerosis(Mesa)[J].Vasc Med,2011,16(4):247-252.
[4]Anping C,Dongdan Z,Ruofeng Q,et al.Lipoprotein-Associated phospholipase a2(Lp-PLA\r,2\r,):A novel and promising biomarker for cardiovascular risks assessment[J].Dis Markers,2013,34(5):323-331.
[5]Lp-PLA(2)Studies Collaboration,Thompson A,Gao P,et al.Lipoprotein-associated phospholipase A(2)and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies[J].Lancet,2010,375(9725):1536-1544.
[6]中国老年学学会心脑血管病专业委员会.脂蛋白相关磷脂酶A2临床应用专家建议[J].中华医学信息导报,2015,30(21):9.
[7]Burke JE,Dennis EA.Phospholipase a2 biochemistry[J].Cardiovascular Drugs and Therapy,2009,23(1):49-59.
[8]Tellis CC,Tselepis AD.Pathophysiological role and clinical significance of lipoprotein-associated phospholipase A2(Lp-PLA2)bound to LDL and HDL[J].Curr Pharm Des,2014,20(40):6256-6269.
[9]Kolodgie FD,Burke AP,Skorija KS,et al.Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis[J].Arterioscler Thromb Vasc Biol,2006,26(11):2523-2529.
[10]Tsimikas S,Tsironis LD,Tselepis AD.New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease[J].Arterioscler Thromb Vasc Biol,2007,27(10):2094-2099.
[11]Chauffe RJ,Wilensky RL,Mohler IE.Recent developments with Lipoprotein-Associated phospholipase a(2)inhibitors[J].Curr Atheroscler Rep,2010,12(1):43-47.
[12]Shi Y,Zhang P,Zhang LF,et al.Role of lipoprotein-associated phospholipase A(2)in leukocyte activation and inflammatory responses[J].Atherosclerosis,2007,191(1):54-62.
[13]Carpenter KL,Challis IR,Arends MJ.Mildly oxidised LDL induces more macrophage death than moderately oxidised LDL: roles of peroxidation, lipoprotein-associated phospholipase A2 and PPARgamma[J].FEBS Lett,2003,553(1):145-150.
[14]Gautier EL,Huby T,Witztum JL,et al.Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage[J].Circulation,2009,119(13):1795-1804.
[15]Perez R,Balboa MA,Balsinde J.Involvement of group VIA calcium-independent phospholipase A(2)in macrophage engulfment of Hydrogen peroxide-treated U937 cells[J].Journal of Immunology,2006,176(4):2555-2561.
[16]Aprahamian T,Rifkin I,Bonegio A,et al.Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease[J].Journal of Experimental Medicine,2004,199(8):1121-1131.
[17]Quinn M,Parthasarathy S,Steinberg D.Lysophosphatidylcholine: a chemotactic factor for humanmonocytes and its potential role inatherogenesis[J].Proc Natl Acad Sci USA,1988, 85(8):2805-2809.
[18]Gonçalves I,Edsfeldt A,Ko NY,et al.Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation[J].Arterioscler Thromb Vasc Biol,2012,32(6):1505-1512.
[19]Ghosh M,Tucker DE,Burchett S,et al.Properties of the group 1V phospho1ipaseA2 fami1y[J].Prog Lipid Res,2006,45(6):487-510.
[20]Donato LJ,Meeusen JW,Callanan H,et al.Advantages of the lipoprotein-associated phospholipase A2 activity assay[J].Clin Biochem,2016,49(1/2):172-175.
[21]Feng LM,Feng GF,Chen Y.Evaluation of lipoprotein-associated phospholipase A2 in healthy Chinese Han adult serum[J].Lipids Health Dis,2014,13(1):6.
[22]Zheng GH,Chen HY,Xiong SQ,et al.Lipoproteinassociated phospholipase A2 gene V279F polymorphisms and coronary heart disease: a meta-analysis[J].Mol Biol Rep,2011,38(6):4089-4099.
[23]Nelson TL,Biggs ML,Kizer JR,et al.Lipoproteinassociated phospholipase A2(Lp-PLA2)and future risk of type 2 diabetes: results from the Cardiovascular Health Study[J].J Clin Endocrinol Metab,2012,97(5):1695-1701.
[24]QI Y,ZHAO D,JIA Z,et al.A previously unreported impact of a PLA2G7 gene polymorphism on the plasma levels of lipoprotein associated phospholipase A2 activity and mass [J].Sci Rep,2016,6(1):37465.
[25]M Hiramoto, H Yoshida, T Imaizumi, et al. A mutation in plasma platelet-activating factor acetylhydrolase(vaI1279→phe)is a genetic risk factor for stroke[J].Stroke,1997,28(12):2417-2420.
[26] Liu X,Zhu RX,Tian YL,et al.Association of PLA2G7 gene polymorphisms with ischemic stroke in northern Chinese Han population[J].Clin Biochem,2014,47(6):404-408.
[27] S Li,Y Ye.Correlations of Lp-PLA2 activity and gene polymorphism with ischemic cerebral stroke[J].Lab Med,2016,31(10):869-873.
[28] Wang T,Karino,K,et al.Effects of G994T in the Lp-PLA2 gene on the plasma oxidized LDL level and carotid Intima-Media thickness in Japanese:the shimane study[J].Am J Hypertens,2009,22(7):742-747.
[29] Ni J,Gu H,Hu WH,et al.Association of Lp-PLA2 G994T gene polymorphism with risk of ischemic stroke in Chinese population[J].J Biochem Mol Toxicol,2017,31(12):e21999.
[30] Croons V,De Meyer I,Houten SM,et al.Effect of statins on the viability of macrophages and smooth muscle cells[J].J Cardiovasc Pharmacol,2010,55(3):269-275.
[31] McConnell JP,Hoefner DM.Lipoprotein-associated phospholipase A2[J].Clin Lab Med,2006,26(3):679-697.
[32] Qiao Z,Ren J,Chen H.Simvastatin reduces expression and activity of lipoprotein-associated phospholipase a(2)in the aorta of hypercholesterolaemic atherosclerotic rabbits[J].Journal of International Medical Research,2009,37(4):1029-1037.
[33] Pedersen MW,Koenig W,Christensen JH,et al.The effect of Marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA(2)in healthy adults[J].Eur J Nutr,2009,48(1):1-5.
[34] Macphee CH,Nelson JJ,Zalewski A.Lipoproteinassociated phospholipase A2 as a target of therapy [review][J].Curr Opin Lipidol,2005,16(4):442-446.
[35] Saougos VG,Tambaki AP,Kalogirou MA,et al.Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A(2)[J].Arterioscler Thromb Vasc Biol,2007,27(10):2236-2243.
[36] Mohler ER,Ballantyne CM,Davidson MH,et al.The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-bl[J].J Am Coll Cardiol,2008,51(17):1632-1641.
[37] Wilensky RL,Shi Y,Mohler ER,et al.Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development[J].Nat Med,2008,14(10):1059-1066.
[38] Serruys PW,Garcia-Garcia HM,Buszman PA,et al.Effects of the direct lipoprotein-associated phospholipase A(2)inhibitor darapladib on human coronary atherosclerotic plaque[J].Circulation,2008,118(11):1172-1182.
[39] Fenning RS,Burgert ME,Hamamdzic D,et al.Atherosclerotic plaque inflammation varies between vascular sites and correlates with response to inhibition of lipoprotein-associated phospholipase A2[J].J Am Heart Assoc,2015,4(2):e001477.
[40] STABILITY Investigators,White HD,Held C,et al.Darapladib for preventing ischemic events in stable coronary heart disease[J].N Engl J Med,2014,370(18):1702-1711.
[41] O'donoghue ML,Braunwald E,White HD,et al.Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial[J].JAMA,2014,312(10):1006-1015.
[42] Cucchiara BL,Messe SR,Sansing L,et al.Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA[J].Stroke,2009,40(7):2332-2336.
[43] Delgado P,Chacón P,Penalba A,et al.Lipoprotein-associated phospholipase A(2)activity is associated with large-artery atherosclerotic etiology and recurrent stroke in TIA patients[J].Cerebrovasc Dis,2012,33(2):150-158.
[44] Lin JX,Zheng HW,Cucchiara BL,et al.Association of Lp-PLA(2)-A and early recurrence of vascular events after TIA and minor stroke[J].Neurology,2015,85(18):1585-1591.
[45] Wei L,Ke Z,Zhao Y,et al.The elevated lipoprotein-associated phospholipase A2 activity is associated with the occurrence and recurrence of acute cerebral infarction[J].Neuroreport,2017,28(6):325-330.
[46] Tian Y,Jia H,Li S,et al.The associations of stroke,transient ischemic attack,and/or stroke-related recurrent vascular events with Lipoprotein-associated phospholipase A2[J].Medicine,2017,96(51):e9413.
[47] Li DZ,Wei W,Ran X,et al.Lipoprotein-associated phospholipase A2 and risks of coronary heart disease and ischemic stroke in the general population: A systematic review and meta-analysis[J].Clinica Chimica Acta,2017,471:38-45.
[48] Feng Z,Yukai L,Hongchao S,et al.Relation between lipoprotein-associated phospholipase A2 mass and incident ischemic stroke severity[J].Neurological Sciences,2018,39(9):1591-1596.
[49] Wencui X,Zhongyang H U,Zhi S,et al.Meta-analysis for the relationship between lipoproteinassociated phospholipase A2 and ischemic stroke[J].Journal of Central South University(Medical Science),2017,42(2):208-214.